Filing Details

Accession Number:
0000897069-24-000227
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-31 16:34:20
Reporting Period:
2024-01-30
Accepted Time:
2024-01-31 16:34:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1533743 Processa Pharmaceuticals Inc. PCSA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1361896 W Justin Yorke C/O Processa Pharmaceuticals, Inc.
7380 Coca Cola Drive, Suite 106
Hanover MD 21076
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-30 8,000 $2.69 31,232 No 4 P Indirect By Richland Fund, LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Richland Fund, LLC
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,737 Direct
Footnotes
  1. Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.